IP Library Granted Patent US 9,333,184
Granted Patent B2
US 9,333,184 · App. 13/692,242 · Granted May 10, 2016

Composition and method for affecting male and female hormone levels

Inventors: Richard J Bendera (Scottsdale, AZ); Leanna S Wilson (Scottsdale, AZ)
Assignee: NOKOMIS RESEARCH, INC.
A61K31/132
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,333,184
App. No.
13/692,242
Granted
May 10, 2016
Kind
B2
Abstract

A composition and method for enhancing fertility of a male or female human by affecting levels of cortisol, dehydroepiandrosterone sulfate, testosterone, progesterone, and estradiol in the human. The composition comprises effective amounts of spermine and spermidine, administered at least once daily for a period of at least thirty days.

Claims (32)

1. A method of treating a human male experiencing estrogen dominance comprising the steps of:

identifying a level of at least one hormone in the human that is causing the estrogen dominance, wherein the at least one hormone is selected from the group consisting of cortisol, dehydroepiandrosterone sulfate, testosterone, progesterone, and estradiol;

providing a composition that comprises between approximately 2.5 mg and 2.7 mg spermine and between approximately 2.5 mg and 2.7 mg spermidine;

administering the composition to the human daily for a period of at least thirty days;

modifying the level of the at least one hormone in order to decrease production of estrogen in the human; and

decreasing progesterone levels in the human after thirty days of treatment.

2. The method of claim 1 further comprising the step of administering the composition to the human at least once daily.

3. The method of claim 1 further comprising the step of administering the composition to the human for a period between thirty days and sixty days.

4. The method of claim 1 further comprising the step of reducing cortisol levels in the human after thirty days of treatment.

5. The method of claim 1 further comprising the step of decreasing estradiol levels in the human after thirty days of treatment.

6. A method for treating hormonal imbalance in a human male, the method comprising the steps of:

identifying a level of at least one hormone in the human, wherein the at least one hormone is selected from the group consisting of cortisol, dehydroepiandrosterone sulfate, testosterone, progesterone, and estradiol;

identifying an imbalance of the at least one hormone in the human;

administering a composition at least once daily to the human consisting of between approximately 2.5 mg and 2.7 mg spermine and between approximately 2.5 mg and 2.7 mg spermidine for a period of at least thirty days;

modifying the level of the at least one hormone that is imbalanced and

decreasing progesterone levels in the human after thirty days of treatment.

7. The method of claim 6 further comprising the step of reducing cortisol levels in the human after thirty days of treatment.

8. The method of claim 6 further comprising the step of decreasing estradiol levels in the human after thirty days of treatment.

9. A method of treating a human male experiencing estrogen dominance comprising the steps of:

identifying a level of at least one hormone in the human that is causing the estrogen dominance, wherein the at least one hormone is selected from the group consisting of cortisol, dehydroepiandrosterone sulfate, testosterone, progesterone, and estradiol;

providing a composition that comprises between approximately 2.5 mg and 2.7 mg spermine and between approximately 2.5 mg and 2.7 mg spermidine;

administering the composition to the human daily for a period of at least thirty days;

modifying the level of the at least one hormone in order to decrease production of estrogen in the human; and

reducing cortisol levels in the human after thirty days of treatment.

10. A method of treating a human male experiencing estrogen dominance comprising the steps of:

identifying a level of at least one hormone in the human that is causing the estrogen dominance, wherein the at least one hormone is selected from the group consisting of cortisol, dehydroepiandrosterone sulfate, testosterone, progesterone, and estradiol;

providing a composition that comprises between approximately 2.5 mg and 2.7 mg spermine and between approximately 2.5 mg and 2.7 mg spermidine;

administering the composition to the human daily for a period of at least thirty days;

modifying the level of the at least one hormone in order to decrease production of estrogen in the human; and

decreasing estradiol levels in the human after thirty days of treatment.

11. A method of treating a human female experiencing estrogen dominance comprising the steps of: identifying a level of at least one hormone in the human that is causing the estrogen dominance, wherein the at least one hormone is selected from the group consisting of cortisol, dehydroepiandorsterone sulfate, testosterone, progesterone, and estradiol; providing a composition that comprises between approximately 2.5 mg and 2.7 mg spermine and between approximately 2.5 mg and 2.7 mg spermidine; administering the composition to the human daily for a period of at least thirty days; modifying the level of the at least one hormone in order to decrease production of estrogen in the human; and increasing dehydroepiandrosterone sulfate levels in the human after thirty days of treatment.

12. A method of treating hormonal imbalance in a human female, the method comprising the steps of: identifying a level of at least one hormone in the human, wherein the at least hormone is selected from the group consisting of cortisol, dehydroepiandorsterone sulfate, testosterone, progesterone, and estradiol; identifying an imbalance of the at least one hormone in the human; administering a composition at least once daily to the human consisting of between approximately 2.5 mg and 2.7 mg spermine and between approximately 2.5 mg and 2.7 mg spermidine for a period of at least thirty days; modifying the level of the at least one hormone that is imbalanced; and increasing dehydroepiandrosterone sulfate levels in the human after thirty days of treatment.

Assignments (2)
SECURITY INTEREST Recorded Feb 21, 2024
From: NOKOMIS RESEARCH INC.
To: AMBOUR HOLDINGS INC.
Reel/Frame 066512/0119 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2013
From: BENDERA, RICHARD J.; WILSON, LEANNA S.
To: NOKOMIS RESEARCH, INC.
Reel/Frame 029839/0439 →
Continuity (2)
Provisional Application 61566647 · Dec 3, 2011
Related Publication 20140155492A1 · Jun 5, 2014